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Lung cancer is the leading cause of cancer mortality in the United States. The 
development of drug resistance with cisplatin or platinum/taxane combination 
chemotherapies has led patients to suffer from recurrent lung cancer. These 
chemotherapy treatments target cancer cells but leave behind cancer stem cells 
(CSCs). CSCs are stem-like tumor cells that have the potential to differentiate and 
proliferate. This allows the cancer to relapse even after initial elimination of the tumor. 
Investigations were performed on a secondary metabolite from the Myrothecium fungus 
family called Verrucarin J (VJ) to see its effects in lung cancer cell lines. VJ significantly 
inhibits cell proliferation in lung cancer cell lines A549 and H1793. The IC50 of VJ was 
approximately 10 nM in A549 after 48 h of treatment and 20 nM in H1793 after 72 h of 
treatment. Treatment of the A549 cell line with VJ induced apoptosis and reduced 
expression levels of key markers and genes found in cancer stem cells, such as 
ALDH1, Notch1, HEY1, CD 133, Oct 4, β-catenin, WNT1, TCF-4, and LGR5, in a dose-
dependent manner. The mechanism that VJ targets the lung cancer cells and CSCs is 
currently being investigated by considering the WNT canonical signaling pathway. 
Treatment of the GSK-3 inhibitor (CHIR99021) in A549 cell lines increased expression 
levels of specific canonical WNT signaling pathway genes including β-catenin, Cyclin 
D1, LGR5, c-Myc and TCF-4. Preliminary results of the combination treatment of VJ and 
GSK-3 inhibitor in A549 cell line indicate that VJ potentially targets the WNT canonical 
signaling pathway. However, further experiments are needed to confirm where exactly 
VJ is targeting that pathway. From these experiments, Verrucarin J has the potential 




Lung cancer is the leading cause of cancer mortality in the United States for both 
males and females [1]. It is estimated that there will be 222,500 new cases of lung 
cancer in 2017 [1]. Two major types of lung cancer are non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common type making 
up 85% of lung cancer cases [2]. SCLC is the more aggressive form that constitutes 
15% of the lung cancer cases. There have been substantial improvements in the 
treatment of lung cancer throughout the years. Surgery and radiation have shown to be 
effective in dealing with localized/regionalized earlier stages of lung cancer. 
Administration of chemotherapeutic drugs like cisplatin along with pacitaxel/docetaxel 
are deemed effective initially. However, more progress is needed to be made for 
patients with advanced stages of lung cancer.  
The use of chemotherapy is effective in some patients, but there are a select view 
who don’t receive promising results. The 5-year survivability rates of lung cancer remain 
low at an average of 18% [1]. A big contributor to recurrent lung cancer and low 
survivability rates is drug resistance to chemotherapeutic drugs such as cisplatin [5-7]. 
Cisplatin is a widely used anti-cancer drug that forms platinum complexes, which 
causes the formation of intrastrand and interstrand DNA cross links [2,6]. This prevents 
lung cancer cells from proliferating, leading to DNA damage and eventually cell death 
[2]. A potential mechanism of drug resistance toward cisplatin includes increased DNA 
repair capacity with the excision repair cross-complementation group 1 (ercc1) and 
breast cancer susceptibility gene 1 (BRCA1) genes [2]. These genes play crucial roles 
in chemoresistance.  
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Studies have shown the potential root to this drug resistance comes from cancer 
stem cell (CSCs). CSCs are a small subpopulation of stem-like tumor cell that can 
differentiate and proliferate [3]. They are known to be resistant to chemotherapeutic 
drugs and radiation, which allows for the reoccurrence of the cancer and tumor 
progression. It is believed that CSCs are surviving the current treatments due to their 
activation of anti-apoptotic pathways, increased telomere length, increased membrane 
transporter activity and the CSCs’ abilities to metastasize [4]. Current treatments are 
killing the cancer cells but leaving behind the cancer stem cells [Fig. 1]. Therefore, there 
is a dire need to develop an innovative way to target not only lung cancer cells, but also 











Figure 1. The Targeting of Cancer Stem Cells. 
Cancer stem cells are “stem-like” tumor cells that have the potential to differentiate, self-
renew, and proliferate. The most accepted theory about cancer stem cells is that they 




This project is focused on identifying an anti-cancer compound that can effectively 
target cancer cells, as well as cancer stem cells in lung cancer. This led to examining 
the anti-cancer activity of a purified fungus compound called Verrucarin J (VJ). VJ is a 
cytotoxic secondary metabolite that comes from the Myrothecium fungus [4]. The 
molecular formula of this compound is C27H32O8. Its anti-cancer activity is unknown. 
However, after previous experiments to see its effectiveness in targeting ovarian cancer 
cells and cancer stem cells, VJ has the potential to be developed into a novel 
chemotherapeutic drug [4]. The specific aims to be addressed in this project include 
determining if VJ can target lung cancer cells/ CSCs and to define the potential self- 
renewal mechanisms which Verrucarin J targets lung cancer cells and CSCs. Verrucarin 
J inhibits cell proliferation in lung cancer cells and CSCs by inducing apoptosis, 
targeting the canonical WNT signaling pathway and reducing the expression levels of 
key stem cell markers and genes. 
 
MATERIALS AND METHODS 
Cell Proliferation Assay using MTT Reagent 
Cell proliferation assay with MTT reagent was conducted to measure the cell 
proliferation rate and the reduction in cell viability in treated lung cancer cells.  Cell lines 
A549 and H1793 were used. These cell lines are non-small cell lung cancer cells, 
specifically adenocarcinoma cells. The cells lines were received from Dr. Mariusz 
Ratajczak’s lab. Preparation of the compound Verrucarin J (N18282 AnalytiCon) 
involved dissolving the compound in DMSO (dimethyl sulfoxide) and making a 10 mM 
stock solution.  The A549 and H1793 cells were rinsed with phosphate-buffered saline 
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(Sigma), trypsinized, and plated into 96-well plates (in a final volume of 100 μl per well). 
Cells were grown in Roswell Park Memorial Institute (RPMI) medium (Sigma) modified 
with 10% FBS (Fetal Bovine Serum). FBS was added to assist in growth and 
proliferation of the cells.  After 24 h in an incubator at 37°C, the medium was replaced 
with the RPMI medium containing 5% FBS.  
Cells were treated in triplicates with VJ at concentrations 0, 1, 2, 5, 10, 20 and  
50 nM. There were three different treatment periods: 24, 48 and 72 h. After each set 
period, the media of that section of cells were replaced with 100 μl of 5% RPMI media 
and 20 μl of MTT reagent (CellTiter96 System, Promega) in each well. After the 
administration of MTT reagent, cells were incubated at 37°C for approximately 30 min to 
1 h. Cells that are functioning with active mitochondria will react to the yellow MTT 
reagent to produce formazan, a purple product. Cells that are dead or do not have 
functioning mitochondria will not react to the reagent. Cell proliferation was assessed 
through color development using ELISA reader at 490 nm to take the absorbance 
readings [4].  
 
Apoptosis assay using flow cytometry for Annexin V 
Apoptosis assay was conducted to see if VJ induce apoptosis in lung cancer 
cells and to determine at what percentage. A549 cell line was plated into T-150 flasks 
using 10% RPMI media (Sigma). After 24 h of incubation at 37°C, cells were treated 
with VJ at concentrations 0, 5, 10, 20, 50 nM for 24 h and were harvested. Cells were 
collected by centrifuging at 1,500 rpm for 5 min and resuspended in Annexin V binding 
buffer (FITC Annexin V Apoptosis Detection Kit, BD Pharmingen) according to 
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supplier’s instructions. FITC (fluorescein isothiocyanate) is a fluorescence marker 
conjugated to the Annexin V. To ensure that cells were not clumped and were single 
cells, they were passed through nylon mesh and diluted to a final concentration of 
10×106 cells/ml. The 100 μL of cell suspension (1×106 cells) was used for each assay. 
For each concentration of VJ, an independent control was used. To each sample except 
controls, 2 μL of Annexin V from the kit was added, and was incubated for 15 min at 
room temperature in the dark. After completion of incubation, 400 μL of binding buffer 
was added and immediately analyzed by Fluorescence- Activated Cell Sorting (FACS) 
analysis using the FACSCalibur (BD BioSciences). The stained and unstained cells 
were analyzed using FlowJo software [4]. 
 
Expression of genes using real-time PCR  
Real-time PCR (Polymerase Chain Reaction) was conducted to see the effect of 
VJ on the gene expression of key CSC markers in lung cancer cells. To test this, A549 
cells were plated in three T-150 flasks, containing 10% RPMI media. After 24 h of 
plating, the media was replaced with 5% RPMI media and the cells were treated with VJ 
at concentrations 0, 10, and 20 nM. After 48 h of treatment, cells were harvested and 
rinsed twice with PBS. The total RNA from each sample was purified following the 
instructions from the RNeasy Mini Kit (Qiagen) and quantitated using NanoDrop. Then 
first strand cDNA was prepared using the iScript cDNA synthesis kit (Bio-Rad) for each 
of the samples. The first cDNA prepared from each sample was subjected to gene 
amplification in real-time PCR.  
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Preparation of the real-time PCR involved making a master mix for each selected 
gene. This master mix included RNA-free water (Sigma), the forward and reverse 
primers of the selected genes and FastStart Universal SYBR Green Master with ROX 
(Sigma). Volumes for each component on the master mix were determined by the 
supplier’s instructions in the SYBR Green Master. The specific primers used for each 
gene were the reverse and forward of Wnt1, β-Catenin, TCF-4, Notch1, Hey1, LGR5, 
ALDH1, Oct 4. and CD 133.   The sequences of the primers are listed in Table 1. Then 
18 µL of the master mix were added to each well in the PCR plate (ThermoFisher). 2 µL 
of the 1st strand cDNA from the 3 samples were added to the respective the wells. Each 
sample was tested in triplicates. The plate was then sealed and put in the centrifuge for 
2 minutes at a speed of 1000-1500 rpm. Then the plate was inserted in a real-time PCR 
detection system (Applied Biosystems StepOnePlus™ Real-Time PCR System). The 
experiment ran for 45 cycles. The Cycle Threshold (CT) values of each of the genes 
were normalized with the CT values for GAPDH used as an internal control [4].  
 A549 cells were also treated with a GSK-3 inhibitor (CHIR99021 Sigma). This 
inhibitor blocks the function of glycogen synthase kinase 3 and increases self-renewal 
of stem cells [10].  The A549 cells were plated in five T-150 flasks, containing RPMI 
media with 10% FBS. After 24 h of plating, the media was replaced with RPMI media 
with 5%FBS. A 5 mM stock solution was prepared for the GSK-3 inhibitor. The cells 
were then treated with the inhibitor at concentrations 0, 1, 3 and 5 µM. After 24 h of 
treatment, the cells from each of the 5 samples were harvested. RNA extraction for 
each of the treated samples occurred using the RNeasy Mini Kit. 1st strand cDNA was 
made for each of the samples. Real-Time PCR was conducted as described previously 
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and the specific primers used for each gene were the reverse and forward of β-Catenin, 
TCF-4, c-Myc, Cyclin D1 and LGR5. The sequences of the primers are listed in Table 1. 
 Then the treatment of A549 cells also included the use of both VJ and GSK-3 
inhibitor. The A549 cells were plated in six T-150 flasks, containing RPMI media with 
10% FBS. After 24 h of plating, the media were replaced with RPMI media with 5% 
FBS. One of the flasks was labeled as the control, only containing A549 cells treated 
with DMSO. Then 4 flasks were treated with the GSK-3 Inhibitor at concentrations 1 and 
3 µM. Then 3 hours later, 2 of those 4 (1 and 3 µM) flasks were treated with VJ at a 
concentration 10 nM. Then the 6th flask only received the treatment of VJ at 10 nM. The 
6 samples were labeled as such: control (0 nM), 10 nM (VJ), 1 µM (GSK-3), 3 µM  
(GSK-3),  10 nM (VJ)+ 1 µM (GSK-3), and 10 nM (VJ)+ 3 µM (GSK-3). After 24 h of 
treatment, RNA extraction occurred, 1st strand cDNA was made and real-time PCR was 
conducted as described previously. The specific primers used for each gene were the 
reverse and forward of TCF-4, Oct 4, Cyclin D1 and ALDH1. The sequences of these 
primers are listed in Table 1.  
 
Selection of Primers for real-time PCR 
Primer selection was determined after review of literature on key stem cell 
markers found in lung cancer stem cells and important genes in the WNT Canonical 
signaling pathway. Particularly, ALDH1 (aldehyde dehydrogenase 1) and CD 133 are 
popular cancer stem cell marker. ALDH1 is known for its regulation of cell differentiation 
and gene expression. Further research has shown ALDH1 positive cells express stem-
like characteristics, making it a key marker for CSCs in lung cancer [4]. Oct 4 is key 
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stem cell marker that highly expressed in stem cells and plays a significant role in the 
maintenance and proliferation of stem cells [14]. The primers were purchased from 
Sigma and their sequences are listed in Table 1. 
 




Gene Sense (Forward) Anti-Sense (Reverse) 
WNT1 CTCTCTTCTTCCCCTTTGTC AACTCGTGGCTCTGTATCC 
β -catenin TGGATGGCCTGCCTCCAGGTGAC ACCAGCCCCTCGAGCCC 
TCF-4 TATGCTCCATCAGCAAGCACTG TGGATGCAGGCTACAGTAGCTG 
Notch 1 TCAGCGGGATCCACTGTGAG ACACAGGCAGGTGAACGAGTTG 
HEY1 TGGATCACCTGAAAATGCTG TTGTTGAGATGCGAAACCAG 
LGR5 GCAAACCTACGTCTGGACAA TGATGCTGGAGCTGGTAAAG 
ALDH1 GCACGCCAGACTTACCTGTC CCACTCACTGAATCATGCCA 
Oct-4 CGCTGGCTTATAGAAGGT ACAGGTGTCATAAGAATGGATA 
CD133 AGTGGCATCGTGCAAACCTG CTCCGAATCCATTCGACGATAGTA 
c-Myc GGACGACGAGACCTTCATCAA CCAGCTTCTCTGAGACGAGCTT 
Cyclin D1 GCATGTTCGTGGCCTCTAAGTA TCGGTGTAGATGCACACAGC 




Student’s t-test was performed to calculate the statistical differences between the 
control and the treated groups. P ≤ 0.05 was considered statistically significant while     
p ≤ 0.001 was considered highly significant. The error bars represent the standard 
deviation of two to three independent experiments [4]. 
 
RESULTS 
Verrucarin J inhibits cell proliferation in A549 and H1793 Cell lines 
  The efficiency of VJ to target lung cancer cells was tested by performing cell 
proliferation assays using a MTT reagent. This experiment involved two different lung 
cancer cell lines, A549 and H1793. Cells were plated into 96-well plates and after 24 h 
and were treated with VJ at concentrations 0,1, 2, 5, 10, 20, and 50 nM. Cell 
proliferation was assayed using MTT assays as described previously in the materials 
and methods section. Treatment of cells with VJ showed a significant dose and time 
dependent inhibition of cell proliferation [Fig. 2]. IC50 values for VJ after treatment of 
cells for 48 h were found to be approximately 10 nM for A549 cell line and 20 nM for 
H1793 cell lin. These results indicate that VJ is a highly potent anti-cancer compound. 
 
Verrucarin J induces apoptosis in A549 cell line 
Apoptosis or programmed cell death is a proccess that regulates cellular 
development. Cancer cells often have missregulated apoptoic pathways that allows for 
uncontrolled cell proliferation to take place [12]. It is important for anti-cancer drugs to 
induce apoptosis in cancer cells to stop the progression of the tumors. To understand 
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how VJ  inhibited the cell proliferation of lung cancer cells, apoptosis assays were 
performed to observe if VJ induces apoptosis.  A549 cells were treated with various 
concentrations of VJ for 24 h . After treatment, cells were washed with PBS, stained 
with Annexin V antibody and analyzed by FACSCalibur as described previously in the 
materials and methods section.  The results from the two experiments showed an 
average of 7.24%, 9.01%, 19.95%, 20.95%, and 22.05% of FITC labeled apoptotic cells 
relative to non-apoptopic cells when treated with VJ at concentrations  0, 5, 10, 20, and 
50 nM, respectively. These results suggest that VJ induces apoptosis in the A549 cell 











































Figure 2.  The Effect of Verrucarin J on Cell Viability in A549 and H1793 Cell Lines 
Lung cancer cells were treated with various concentrations of Verrucarin J. The graphs 
show the percentage of cell viability from 3 experiments per time period: 24, 48, and 72 
h. The mean ± S.D (standard deviation) were plotted using Graph Pad. Asterisks (*, **) 
indicate significant (p ≤ 0.05) and very significant (p ≤ 0.001). From the 48 h time period, 
the IC50 for A549 cell lines was determined to be 10 nM and found to be significant 
when compared to control. For the 72 h time period, the IC50 for H1793 cell lines was 























Figure 3. The Effect on Verrucarin J in inducing apoptosis 
To test induction of apoptosis, we analyzed the A549 cell line by flow cytometry using 
the VJ concentrations of 0, 5, 10, 20 and 50 nM concentrations of Verrucarin J.  Cells 
were analyzed after 24 h of treatment. A) FAC Analysis: The graphs shown are from 
two independent experiments. The percentages of FITC in the treated samples from 
experiment one are 7.58%, 10.1%, 21.4%, 22.4% and 23.3% respectively. The 
percentages of FITC in the treated samples from experiment two are 6.91%, 7,92%, 
18.5%, 19.5%, and 20.8% respectively. The blue section represents the apoptotic cells. 
B) Quantitative analysis: the graph shows the mean ± S.D. (standard deviation) of two 





Verrucarin J inhibits the expression of CSCs markers and genes 
Notch and Wnt pathways are two prominent self-renewal pathways. Specifc 
genes were selected from these pathways due to their pivotal role in cellular 
development and survival. Dysregulation of the Notch pathway promotes tumorgenesis 
and increases upreguation of genes such as Notch1 and HEY1 [13]. The Wnt pathway 
is also known for promoting oncogenesis especially when there is upregulation of         
β-catenin and TCF-4 [14]. Results showed a significant, dose-dependent suppression of 
WNT1, β-catenin, TCF-4, Notch1, HEY1, LGR5, ALDH1, Oct 4. and CD133 genes in 
A549 cells when treated with VJ [Fig. 4]. This decrease in expression by VJ at the RNA 
level suggests VJ has the ability to target cancer stem cells. 
 
GSK-3 Inhibitor increases expression of key genes in WNT Canonical Signaling 
Pathway 
GSK-3 (glycogen synthase kinase 3) regulates transcription and cell proliferation 
in the WNT canonical pathway [11]. A GSK-3 inhibitor was used to inhibit the 
functionality of GSK-3 in the lung cancer cells to increase the production of WNT target 
genes. Various concentrations of the GSK-3 inhibitor were used to treat the A549 cell 
line (0, 1, 3, and 5 µM). Results as shown in Figure 5 indicated an increased, dose-
dependent expression of β-catenin, TCF-4, c-Myc, Cyclin D1 and LGR5 in A549 cells 
when treated with GSK-3 inhibitor.  Cyclin D1, c-Myc, and β-catenin showed significant 
differences in concentrations at 3 and 5 µM. LGR5 showed a significant difference from 
the control in the 3 µM. These results suggest that the GSK-3 inhibitor is increasing the 
expression of key genes in the WNT canonical signaling pathway.   
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Verrucarin J inhibits the WNT Canonical Signaling Pathway 
       To determine the mechanism at which Verrucarin J targets lung cancer cells and 
cancer stem cells, a combination therapy was conducted to see how VJ works with the 
GSK-3 inhibitor in A549 cell line. The combination therapy entailed 6 different sample 
groups; control (0 nM), 10 nM of VJ, 1 µM of GSK-3 inhibitor, 3 µM of GSK-3 inhibitor, 
10 nM of VJ plus 1 µM of GSK-3 inhibitor, and 10 nM of VJ plus 3 µM of GSK-3 
inhibitor. The specific primers selected for this first experiment include ALDH1, TCF-4, 
OCT 4, and Cyclin D1.  Referring to Figure 6, the preliminary results show an increased 
expression of ALDH1, TCF-4, OCT 4, and Cyclin D1 in 1 µM and 3 µM GSK-3 inhibitor 
treatment when compared to the control and the samples treated with 10 nM of VJ. 
After the administration of the two compounds, GSK-3 and VJ, the expression levels of 
these markers decreased compared to the inhibitor only samples [Fig. 6]. This suggests 
that  VJ plays a role in targeting the WNT canonical signaling pathway as its effects are 
neutralized the GSK-3 inhibitor. However, more experiments are needed to further 



































Figure 4. RT-PCR Quantification of various genes  
The graphs show the fold change of WNT1, β-catenin, TCF-4, Notch1, HEY1, LGR5, 
ALDH1, Oct-4 and CD133, respectively. Each graph represents two experiments using 
two different sets of first strand cDNA from the RNA samples of the treated A549 cells.  
The genes were normalized to GAPDH. The amplification level of each gene was 
quantified. The mean ± S.D were plotted using GraphPad.  The asterisk (*) indicates 
significance (p ≤ 0.05).  In WNT1, LGR5, Notch1, HEY1, CD133, ALDH1, and Oct-4  
expressions on treatment with 10 nM and 20 nM were shown to be significant. For       






















Figure 5. Treatment with GSK3 Inhibitor: RT-PCR Quantification  
The graphs show the fold change of c-Myc, TCF-4, LGR5, β-catenin and Cyclin D1. 
Graph represents three experiments using two different sets of first strand cDNA from 
the RNA samples of the treated A549 cells. The genes were normalized to GAPDH. The 
amplification level of each gene was quantified using RT-PCR. The mean ± S.D were 
plotted using GraphPad. The asterisk (*) indicates significance (p ≤0.05).  In the c-Myc,    
β-catenin, and Cyclin D1 expressions, treatment with 3 μM and 5 μM were shown to be 








Figure 6. Preliminary Results: VJ inhibits target genes in WNT Signaling Pathway 
The graphs represent one experiment using 1 set of first strand cDNA from the RNA 
samples of the treated A549 cells with the GSK-3 inhibitor and VJ. The genes were 
normalized to GAPDH. The amplification level of each gene was quantified. The genes 





The current process of treating lung cancer has made significant strides over the 
years. However, the progression of this fight is still being inhibited by drug resistance 
and tumor reoccurrence. Patients are dying from this disease everyday as current 
treatments have failed them in eliminating the cancer. At the root of this is cancer stem 
cells. Tumor regression cannot occur due to current treatments not targeting the CSCs. 
Therefore, there needs to be continuous efforts made to develop innovative treatments 
that will effectively target lung cancer cells and cancer stem cells. 
Previously, Dr. Kakar’s lab conducted a search to find a compound that could 
potentially be a solution to preventing recurrent lung cancer. The focus was to find a 
compound that not only has anti-cancer activity but the ability to effectively target cancer 
stem cells as well. This search led to the choice of investigating the effects of Verrucarin 
J, a secondary fungus metabolite. The compound is known to have cytotoxic abilities, 
but its anti-cancer activity remains to be determined [4]. To test its effectiveness in 
targeting lung cancer cells and CSCs, experiments showed how VJ reduced cell 
proliferation in lung cancer cell lines A549 and H1793 in a dose and time-dependent 
manner [Fig. 2]. Further tests were done to determine how VJ inhibited cell proliferation 
and reduced cell viability in these lung cancer cells. Through the induction of apoptosis, 
the increasing concentration of VJ increased the number of apoptotic cells. This 
provides more support in VJ’s anti-cancer capabilities [Fig.3]. 
As shown in Figure 4, the treatment of A549 cells with VJ results in a dose 
dependent suppression of various CSC markers expression levels in RNA. These 
markers include WNT1, β-catenin, TCF-4, Notch1, HEY1, LGR5, ALDH1, Oct-4. and 
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CD 133.  These specific genes were selected due to their involvement in identifying key 
cancer stem cells and their important roles in self-renewal signaling pathways. From 
these results, VJ has the potential to effectively target the CSCs.  
After these promising results, an effort was made to determine which mechanism 
VJ targets the lung cancer cells and cancer stem cells. There is a possibility that there 
are multiple pathways that VJ could target, yet the concentration in this research was on 
the WNT canonical signaling pathway. A key factor of these cancer stem cells is their 
self-renewal capabilities. The WNT signaling pathway is associated with the progression 
and initiation of tumors and signals the cancer cells to proliferate [9,15]. Our previous 
experiments showed reduced expression of key genes such as WNT1, β-catenin and 
TCF-4 when treated with VJ. Therefore, making it appropriate to investigate this 




















Referring to Figure 7, when the WNT ligand is absent, a complex forms and β-
catenin is phosphorylated by CK1(casein kinase 1) and GSK-3 (glycogen synthase 
kinase 3). GSK-3 is a key suppressor in this pathway [10,11]. Both GSK-3 and CK1 
phosphorylate β-catenin and target it for degradation. This then prevents β-catenin from 
entering the nucleus, inhibiting self-renewal and proliferation of the cell [11]. When the 
WNT ligand is present, WNT binds to the receptors on Fz and LRP5/6 and prompts 
LRP/6 to be phosphorylated. With this complex formed, it allows for the stabilization of 
Figure 7: WNT Canonical Signaling Pathway  
This is a representation of the WNT/β-catenin signaling transduction. When WNT is 
absent, a complex forms and β-catenin is phosphorylated by CK1 and GSK-3. This 
then makes β-catenin targeted for degradation and not allowed to enter the nucleus. 
When WNT ligand is present, the receptor from Fz and LRP5/6 bind to WNT and lead 
to LRP/6 to be phosphorylated. With this complex formed, it allows for the 
stabilization of β-catenin. β-catenin travels into the nucleus where it activates gene 
transcription of WNT targeted genes. 
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β-catenin. β-catenin travels into the nucleus where it activates gene transcription of 
WNT targeted genes [8,14]. To initiate defining the mechanism, a GSK-3 inhibitor was 
used to block β-catenin from being targeted. This then allowed β-catenin to accumulate 
and enter the nucleus for transcription to be activated [Fig. 8]. Results from these 
experiments showed that increased concentration of the GSK-3 inhibitor, increased the 
expression levels of key WNT target genes, including c-Myc, TCF-4, β-catenin, Cyclin 
D1 and LGR5 [Fig. 5]. Steps were then taken to see how GSK-3 inhibitor and VJ would 















Figure 8: WNT Canonical Signaling Pathway with GSK-3 Inhibitor  
This is a representation of the WNT/β-catenin signaling transduction with an addition of 
a GSK-3 inhibitor. By blocking the function of GSK-3, the inhibitor allows for β-catenin to 




The process of this combination therapy with these two compounds involved 
treating the A549 cells at different time points to prevent the compounds from canceling 
each other’s’ effects. Therefore, the inhibitor at concentrations of 1 µM and 3 µM were 
first administered to the cells following the VJ concentration of 10 nM (which was the 
previously determined IC50 of VJ in the A549 cell line.  In total, there are 6 groups: 
control, 10 nM of VJ, 1 µM of GSK-3 Inhibitor (CHIR99021), 3 µM GSK-3 Inhibitor 
(CHIR99021), 10 nM of VJ plus 1 µM of GSK-3 Inhibitor (CHIR99021), and 10 nM of VJ 
plus 3 µM GSK-3 Inhibitor (CHIR99021). After one experiment testing 4 genes (ALDH1, 
Oct-4, TCF-4, and Cyclin D1), the GSK-3 inhibitor is neutralizing the effects of VJ when 
used in combination together [Fig. 6]. However, furthering testing is needed to confirm 
these preliminary results. Tentatively, the results support a potential mechanism in how 
VJ targets these lung cancer cells and CSCs. This consistently adds further value in VJ 
being a potential chemotherapeutic drug. 
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